- Home
- ACRE vs AVIR Comparison
ACRE vs AVIR Comparison
Compare ACRE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- AVIR
- Stock Information
- Founded
- ACRE 2011
- AVIR 2012
- Country
- ACRE United States
- AVIR United States
- Employees
- ACRE N/A
- AVIR N/A
- Industry
- ACRE Real Estate Investment Trusts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ACRE Real Estate
- AVIR Health Care
- Exchange
- ACRE Nasdaq
- AVIR Nasdaq
- Market Cap
- ACRE 264.6M
- AVIR 273.0M
- IPO Year
- ACRE 2012
- AVIR 2020
- Fundamental
- Price
- ACRE $4.66
- AVIR $3.90
- Analyst Decision
- ACRE Hold
- AVIR Hold
- Analyst Count
- ACRE 6
- AVIR 1
- Target Price
- ACRE $5.58
- AVIR $6.00
- AVG Volume (30 Days)
- ACRE 399.9K
- AVIR 426.9K
- Earning Date
- ACRE 08-05-2025
- AVIR 08-06-2025
- Dividend Yield
- ACRE 12.88%
- AVIR N/A
- EPS Growth
- ACRE N/A
- AVIR N/A
- EPS
- ACRE N/A
- AVIR N/A
- Revenue
- ACRE $67,129,000.00
- AVIR N/A
- Revenue This Year
- ACRE N/A
- AVIR N/A
- Revenue Next Year
- ACRE N/A
- AVIR N/A
- P/E Ratio
- ACRE N/A
- AVIR N/A
- Revenue Growth
- ACRE 83.51
- AVIR N/A
- 52 Week Low
- ACRE $3.35
- AVIR $2.46
- 52 Week High
- ACRE $7.89
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- ACRE 48.67
- AVIR 67.66
- Support Level
- ACRE $4.39
- AVIR $3.36
- Resistance Level
- ACRE $4.68
- AVIR $3.53
- Average True Range (ATR)
- ACRE 0.13
- AVIR 0.15
- MACD
- ACRE -0.01
- AVIR -0.00
- Stochastic Oscillator
- ACRE 54.00
- AVIR 97.24
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).